Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash Flows from Operating Activities
Net income (loss)	$ (49.1)	$ 31.5
Adjustments to reconcile net income (loss) to cash flows from operating activities:
Depreciation and amortization	81.5	75.2
Change in deferred income taxes	(25.1)	16.3
Stock-based compensation expense	11.1	7.7
Asset impairment charges	0.0	4.0
Gain on sale of assets	(3.8)	0.0
Changes in operating assets and liabilities	(9.8)	(117.2)
Other non-cash operating activities, net	(0.5)	(9.4)
Net Cash Provided by (Used for) Operating Activities	4.3	8.1
Cash Flows from Investing Activities
Net purchases of property and equipment	(12.6)	(28.0)
Proceeds from settlement of net investment hedges (Note 11)	25.2	0.0
Purchases of software	(31.8)	(2.5)
Other investing activities, net	(0.4)	(0.5)
Net Cash Used for Investing Activities	(19.6)	(31.0)
Cash Flows from Financing Activities
Repayments of borrowings (Note 10)	(371.4)	(7.5)
Proceeds from issuance of long-term debt (Note 10)	79.2	0.0
Proceeds from issuance of common stock and tangible equity units (Note 9)	1,219.9	0.0
Debt issuance costs	(3.1)	0.0
Consideration paid to Lilly in connection with the Separation (Note 1)	0.0	(175.1)
Other net financing transactions with Lilly	(15.2)	(156.4)
Other financing activities, net	(12.8)	(0.5)
Net Cash Provided by (Used for) Financing Activities	896.6	(339.5)
Effect of exchange rate changes on cash and cash equivalents	(9.3)	(14.5)
Net increase (decrease) in cash, cash equivalents and restricted cash	872.0	(376.9)
Cash, cash equivalents and restricted cash at beginning of period	345.1	677.5
Cash, cash equivalents and restricted cash at end of period	1,217.1	300.6
Cash, cash equivalents and restricted cash	$ 1,217.1	$ 300.6